文献速递慢性静脉疾病

ThermoBlock射频消融治疗慢性大隐静脉功能不全的两年结局:910例单中心经验

Two-year outcomes of ThermoBlock radiofrequency ablation in chronic saphenous vein insufficiency: A single-center experience with 910 cases.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2025-11-21

本研究为单中心回顾性研究,纳入910例接受ThermoBlock射频消融的慢性大隐静脉功能不全患者,评估技术成功率、安全性和临床结局。结果显示3个月技术成功率为97.6%,静脉临床严重程度评分和生活质量显著改善,大隐静脉直径显著缩小,主要并发症发生率低。

要点

  • ThermoBlock射频消融治疗慢性大隐静脉功能不全3个月技术成功率达97.6%。
  • 静脉临床严重程度评分从10.9±2.4降至3.6±0.9,生活质量评分显著提高。
  • 主要并发症罕见,无死亡和肺栓塞,深静脉血栓发生率为0.7%。

核心结论

  • ThermoBlock射频消融是治疗慢性大隐静脉功能不全安全有效的方法,静脉闭合率高、症状缓解显著且生活质量改善。

研究设计与样本

  • 单中心回顾性研究,纳入910例(男444例,女466例;平均年龄45.4±11.5岁)接受ThermoBlock射频消融的患者,时间范围为2019年3月至2023年6月。

主要发现

  • 3个月技术成功率为97.6%。
  • 静脉临床严重程度评分从10.9±2.4改善至3.6±0.9(P < .001;Cohen's d = 3.7)。
  • VEINES-QOL/Sym评分从60.5±7.71提高至84.6±8.52(P < .001;Cohen's d = 3.0)。
  • 大隐静脉平均直径从术前7.33±1.13 mm降至3个月时5.39±0.60 mm和24个月时2.94±0.66 mm(P < .001)。
  • 无死亡或肺栓塞发生;深静脉血栓发生率为0.7%,次要并发症包括血栓性静脉炎(10.3%)、色素沉着(11.9%)、瘀斑(10.9%)和麻木(24.7%)。

临床怎么用

  • ThermoBlock射频消融可作为慢性大隐静脉功能不全的一线治疗选择,尤其适用于大直径大隐静脉患者。

局限性

  • 本研究为单中心回顾性设计,可能存在选择偏倚和随访不完整等局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic venous insufficiency is a common vascular disorder that can lead to significant morbidity if left untreated. Endovenous thermal ablation, particularly radiofrequency ablation (RFA), has become a first-line therapy owing to its high efficacy and favorable safety profile. We sought to evaluate the technical success, safety, and clinical outcomes of the ThermoBlock RFA system in patients with reflux grade 4 great saphenous vein (GSV) insufficiency. METHODS: This single-center retrospective study included 910 patients (444 males, 466 females; mean age, 45.4 ± 11.5 years) who underwent ThermoBlock RFA between March 2019 and June 2023. Clinical severity was assessed using the Venous Clinical Severity Score, and quality of life (QoL) was measured with the VEINES-QOL/Sym questionnaire. Duplex ultrasound examinations were performed at baseline and at 3, 6, 12, and 24 months. Statistical analyses used paired t tests for continuous variables and Wilcoxon signed-rank tests for ordinal variables, with effect sizes reported. RESULTS: Technical success at 3 months was 97.6%. The Venous Clinical Severity Score improved from 10.9 ± 2.4 to 3.6 ± 0.9 (P < .001; Cohen's d = 3.7), and VEINES-QOL/Sym scores increased from 60.5 ± 7.71 to 84.6 ± 8.52 (P < .001; Cohen's d = 3.0). The mean GSV diameter decreased from 7.33 ± 1.13 mm before the procedure to 5.39 ± 0.60 mm at 3 months and 2.94 ± 0.66 mm at 24 months (P < .001). No mortality or pulmonary embolism occurred; deep vein thrombosis was observed in 0.7% of patients. Minor complications included thrombophlebitis (10.3%), hyperpigmentation (11.9%), ecchymosis (10.9%), and numbness (24.7%). CONCLUSIONS: ThermoBlock RFA is a safe and effective treatment for chronic GSV insufficiency, achieving high vein closure rates, substantial symptom relief, and improved QoL with minimal major complications. Its integrated laser guidance system may enhance procedural precision and support durable long-term outcomes. CLINICAL RELEVANCE: Chronic venous insufficiency is a prevalent condition that significantly impairs QoL and imposes a substantial socioeconomic burden. Endovenous thermal ablation techniques have largely replaced conventional surgery owing to their high efficacy and lower complication rates. The ThermoBlock RFA system integrates precise thermal control with laser-guided catheter positioning, potentially enhancing procedural accuracy and outcomes. In this large, single-center study of 910 patients with advanced saphenous vein insufficiency, ThermoBlock RFA achieved a 97.6% closure rate at 3 months, with marked improvements in Venous Clinical Severity Score and VEINES-QOL/Sym scores, and a low incidence of major complications. These findings support ThermoBlock RFA as a safe, effective, and reproducible first-line option for the treatment of chronic venous insufficiency, even in patients with large-diameter great saphenous veins.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Elci ME, Tekin G. Two-year outcomes of ThermoBlock radiofrequency ablation in chronic saphenous vein insufficiency: A single-center experience with 910 cases. J Vasc Surg Venous Lymphat Disord. 2025. PMID: 41274456. doi:10.1016/j.jvsv.2025.102357

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。